Cadence Pharmaceuticals (NASDAQ: [[ticker:CADX]]), the San Diego-based developer of an intravenous form of acetaminophen for pain relief in hospitals, said today it has obtained an exclusive option to acquire Redwood City, CA-based Incline Therapeutics. Separately, Incline announced it has raised $43 million in Series A venture financing to develop its fentanyl iontophoretic transdermal system (Ionsys), a pain reliever patients can give to themselves following surgery. Cadence also announced it has secured a $30 million debt financing from Oxford Finance, Silicon Valley Bank, and GE Financial Services.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
